Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma

Journal of Thoracic Imaging

Volumn 29, Issue 6, 2014, Pages 357-363

  Hsu, Jui Sheng ^a,b,c   Huang, Ming Shyan ^d,e   Chen, Chiao Yun ^a,b,c   Liu, Gin Chung ^a,b,c   Liu, Ta Chih ^c,e   Chong, Inn Wen ^d,e   Chou, Shah Hwa ^f   Yang, Chih Jen ^a,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Graduate Institute of Clinical Behavioral Science   (Taiwan)

^c Department of Internal Medicine Division of Hematology   (Taiwan)

^d Department of Internal Medicine   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f Department of Surgery Division of Chest Surgery   (Taiwan)

Author keywords

Advanced lung adenocarcinoma; Calcification; Chest computed tomography; EGFR mutation; Exon 19

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHOGRAPHY; CLINICAL FEATURE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; INDEL MUTATION; LUNG ADENOCARCINOMA; LUNG CALCIFICATION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; POINT MUTATION; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIVERSITY HOSPITAL; ADENOCARCINOMA; GENETICS; IMAGE PROCESSING; LUNG; LUNG TUMOR; MIDDLE AGED; MUTATION; OBSERVER VARIATION; PROCEDURES; RADIOGRAPHY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; OBSERVER VARIATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84918511828     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000116     Document Type: Article

References (35)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367-1380.
2. Nishino M, Hatabu H, Johnson BE, et al. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;271:6-27.
3. Nishino M, Jackman DM, Hatabu H, et al. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011;18:424-436.
4. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009;361:1018-1020.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
8. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388.
9. Usuda K, Sagawa M, Motono N, et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev. 2014;15:657-662.
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
11. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-246.
12. Thunnissen E, Van Der Oord K, Den BM. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch. 2014;464:347-358.
13. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-742.
14. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442-2449.
15. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol. 2006;36:69-75.
16. Lee HJ, Kim YT, Kang CH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology. 2013;268:254-264.
17. Choi CM, Kim MY, Lee JC, et al. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy. Radiology. 2014;270:574-582.
18. Onn A, Choe DH, Herbst RS, et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005;237:342-347.
19. Jung CY. Biopsy and mutation detection strategies in nonsmall cell lung cancer. Tuberc Respir Dis (Seoul). 2013;75:181-187.
20. Togashi Y, Masago K, Kubo T, et al. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer. 2011;117:819-825.
21. Obenauer S, Hermann KP, Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol. 2005;15:1027-1036.
22. Khan AN, Al-Jahdali HH, Allen CM, et al. The calcified lung nodule: what does it mean? Ann Thorac Med. 2010;5:67-79.
23. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
24. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75:191-202.
25. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer. 1991;68:1973-1977.
26. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105:595-605.
27. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:3908-3914.
28. Zhu JQ, Zhong WZ, Zhang GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett. 2008;265:307-317.
29. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 2005;128:317-321.
30. Jang TW, Oak CH, Chang HK, et al. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24:48-54.
31. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006;1:231-239.
32. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
33. Yanagawa M, Kuriyama K, Kunitomi Y, et al. One-dimensional quantitative evaluation of peripheral lung adenocarcinoma with or without ground-glass opacity on thin-section CT images using profile curves. Br J Radiol. 2009;82:532-540.
34. Aoki T, Hanamiya M, Uramoto H, et al. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers. Radiology. 2012;264:590-596.
35. Van ZN, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-smallcell lung cancer. Ann Oncol. 2007;18:99-103.